Chimeric antigen receptor copies in cell‐free DNA predict relapse in aggressive B‐cell lymphoma patients treated with CAR T‐cell therapy

Summary Chimeric antigen receptor (CAR) T‐cell therapy has emerged as a transformative treatment for aggressive B‐cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates the detection of CAR copies in circulating cell‐free DNA (cfDNA) as a potentia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2025-01, Vol.206 (1), p.195-203
Hauptverfasser: Iglesia‐San Sebastián, Ismael, López‐Esteban, Miguel, Bastos‐Oreiro, Mariana, Fernández de Córdoba‐Oñate, Sara, Gutierrez, Maravillas, Carbonell, Diego, Bailén, Rebeca, Gómez‐Centurión, Ignacio, Fernández‐Caldas, Paula, Castilla, Lucía, Anguita, Javier, Kwon, Mi, García‐Sanz, Ramón, Buño, Ismael, Martínez‐Laperche, Carolina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Chimeric antigen receptor (CAR) T‐cell therapy has emerged as a transformative treatment for aggressive B‐cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates the detection of CAR copies in circulating cell‐free DNA (cfDNA) as a potential predictive biomarker of early relapse (
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.19916